A Systematic Review of Adherence to Oral Antineoplastic Therapies

Greer, Joseph A.; Amoyal, Nicole R.; Nisotel, Lauren; Fishbein, Joel N.; MacDonald, James; Stagl, Jamie M.; Lennes, Inga T.; Temel, Jennifer S.; Safren, Steven A.; Pirl, William F.

doi:10.1634/theoncologist.2015-0405

Cited by 278 publications

(357 citation statements)

References 94 publications

(90 reference statements)

Supporting

Mentioning

303

Contrasting

Unclassified

Order By: Relevance

“…In sum, the results of this small exploratory study in patients with MM are consistent with a growing body of research suggesting that missed doses of oral anticancer medication are common in cancer patients [24]. Novel interventions targeting adherence to oral anti-cancer agents are beginning to emerge and technology will likely have a role.…”

Section: Discussionsupporting

confidence: 81%

Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study (Preprint)

Asfaw¹,

Yan²,

Sweiss³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study (Preprint)

Asfaw¹,

Yan²,

Sweiss³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…The identification of barriers to medication adherence is also an important factor for the success of pharmacotherapy. Many of the patients with cancer of the studies included in our review were elderly, had difficulty understanding the therapeutic regimen, experienced adverse reactions and/or used many drugs simultaneously; these factors have a significant correlation with poor adherence to antineoplastic drugs . Thus, the pharmacists assessed patient's adherence and sought to optimize drug therapy by providing a simplified dosage schedule that is more appropriate to the patient's routine and habits.…”

Section: Discussionmentioning

confidence: 99%

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

et al. 2017

View full text Add to dashboard Cite

SummaryWhat is known and objectives: Most antineoplastic drugs are highly toxic and have low therapeutic indexes, which can result in drug-related problems. In this context, pharmacist interventions may play an important role in the success of the treatment.The objective of this study was to examine the effects of pharmacist interventions on adult outpatients with cancer using antineoplastic drugs. Methods:A literature search was performed using PubMed, ISI Web of Science and LILACS databases from January 1990 to April 2016, using MeSH terms or text words related to pharmacist interventions, cancer and outpatient care. Studies published in English, Portuguese or Spanish on the effects of pharmacist interventions in outcome measures in adult outpatients with cancer were included. Two independent authors performed study selection and data extraction with a consensus process. The articles were analysed according to previously established criteria, such as country, study design, setting, population, type of cancer, description of the intervention and control groups, outcomes, main conclusions and study limitations. Results and discussion:A total of 874 records were identified, of which 11 satisfied the inclusion criteria. The studies were conducted mainly in the United States and included patients aged >50 years. Most studies had a before-after design. Pharmacist interventions primarily included educating and counselling patients on the management of adverse events. Rates of nausea and vomiting control, medication adherence and patient satisfaction were the most common outcome measures; a significant benefit in these parameters as a result of pharmacist interventions was noted in most studies. What is new and conclusion:The findings from this systematic review indicate that pharmacist interventions can improve outcome measures in outpatients with cancer.However, the collective quality of the studies was poor and gaps identified indicate that further research is needed to provide more robust results. K E Y W O R D Scancer, pharmaceutical care, pharmacists, systematic review

show abstract

“…7,19,20 However, few studies have focused on young women (YW) with BC even though they are a population of particular interest. 7,19,20 However, few studies have focused on young women (YW) with BC even though they are a population of particular interest.…”

Section: Introductionmentioning

confidence: 99%

Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer

Wassermann

Gelber

Rosenberg

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: Young age is a known factor associated with suboptimal adherence to endocrine therapy (ET) for adjuvant breast cancer (BC) treatment. This study was aimed at assessing nonadherent behaviors and associated factors among young women with early-stage hormone receptor-positive BC. METHODS: As part of a multicenter, prospective cohort of women with a diagnosis of BC at or under the age of 40 years, participants were surveyed 30 months after their diagnosis about adherent behaviors. Among those who reported taking ET, adherence was measured with a 3-item Likert-type scale: Do you ever forget to take your ET? If you feel worse when you take your ET, do you stop taking it? Did you take your ET exactly as directed by your doctor over the last 3 months? Women reporting at least 1 nonadherent behavior were classified as nonadherers. Variables with a P value <.20 were included in a multivariable logistic model. RESULTS: Among 384 women, 194 (51%) were classified as nonadherers. Univariate factors that retained significance in the multivariable model included educational level (odds ratio [OR], 0.50 for high vs low; P = .04), level of social support according to the Medical Outcome Study Social Support Survey (OR, 0.98 per 1 point; P = .01), and confidence with the decision regarding ET measured on a 0 to 10 numerical scale (OR, 0.63 for high vs low; P = .04). CONCLUSIONS: Findings from this study could help to identify young patients at higher risk for nonadherence. Interventions adapted to the level of education and aimed at reinforcing support and patients' confidence in their decision to take ET could improve adherence and associated outcomes in this population. Cancer 2019;125:3266-3274.

show abstract

A Systematic Review of Adherence to Oral Antineoplastic Therapies

Cited by 278 publications

References 94 publications

Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study (Preprint)

Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study (Preprint)

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer

Contact Info

Product

Resources

About